All In Biotech

Drug Trial Radar · NCT05422508

Evaluate the Safety and Immunogenicity After MG1111(BARICELA Inj.) as 2nd Vaccination in 4 ~ 6 Year Old Healthy Children With a History of 1st Varicella Vaccination

A Double-blind, Randomized, Multi-Center, Active Controlled Phase 2 Clinical Trial to Evaluate the Safety and Immunogenicity After MG1111(BARICELA Inj.) as 2nd Vaccination in 4 ~ 6 Year Old Healthy Children With a History of 1st Varicella Vaccination

Last checked: Nov 19, 2026Latest source record: Jan 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 230 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

230

Planned (sponsor's estimate)

Start

Jul 5, 2022

Primary completion

Jun 2025

Study completion Jun 2027

Sponsor

Lead sponsor
Green Cross CorporationIndustry
Sponsor type
Industry
First posted
Jun 16, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 4 years, up to 6 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

* Primary objective is to assess the safety of MG1111 until Day 42 using as 2nd vaccination * Secondary objective to assess the immunogenicity and safety of MG1111 using as 2nd vaccination

Conditions

  • Varicella

Interventions

  • MG1111 (BARICELA)Biological

    0.5ml, single dose, subcutaneous injection

  • VARIVAXBiological

    0.5ml, single dose, subcutaneous injection

  • SuduvaxBiological

    0.5ml, single dose, subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of fever (temperature ≥39.0℃)Time frame: within 7 days
  2. Solicited local / systemic adverse eventsTime frame: within 7 days
  3. Unsolicited adverse eventsTime frame: within 42 days
  4. Vital signs (blood pressure, pulse rate, respiration rate and body temperature)Time frame: within 42 days
  5. Incidence of fever (temperature ≥39.0℃)Time frame: within 42days
  6. Physical examinations (Cardiovascular, respiratory, gastrointestinal, liver, metabolic/endocrine, kidney, reproductive, musculoskeletal and nervous system, head/neck, and skin)Time frame: within 42 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Korea University Ansan Hospital

    Ansan, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.